Cytokinetics said Monday that its experimental drug demonstrated statistically significant improvements in blood flow for patients with an inherited form of heart disease — a result that compares favorably to a competing heart drug recently acquired by Bristol Myers Squibb.
In a small, mid-stage clinical trial, 13 of 14 patients, or 93%, treated with a higher dose of the Cytokinetics drug, called CK-274, achieved improvement in blood flow to a target level where they no longer met the threshold for being diagnosed with their disease — obstructive hypertrophic cardiomyopathy, or HCM. No concerning or unexpected side effects were reported.
The response rate to a lower dose of CK-274 was 79% — and both dose groups easily outperformed the 8% response rate reported for patients offered placebo during the 10-week study.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
